ALKERMES | ALKS - Gewinn Vor Steuern





Gewinn Vor Steuern Veränderung Datum
AbbVie USD 5.57B 2.9B 2026-03
Acadia Pharmaceuticals USD 3.98M 22.34M 2026-03
ALKERMES USD -61.93M 122.3M 2026-03
Amgen USD 1.51B 2.41B 2025-12
Biogen USD 377.7M 433.7M 2026-03
BioMarin Pharmaceutical USD 141.2M 168.36M 2026-03
Bristol-Myers Squibb USD 1.47B 1.64B 2025-12
Coherus Biosciences USD -46.35M 90.86M 2025-12
Eli Lilly USD 8.27B 1.03B 2025-12
Gilead Sciences USD 2.08B 1.56B 2025-12
Heron Therapeutics USD -2.95M 14.54M 2025-12
Ionis Pharmaceuticals USD -93M 135M 2026-03
J&J USD 7.82B 2.86B 2026-03
Merck USD 3.42B 3.32B 2025-12
Minerva Neurosciences USD 22.51M 30.74M 2024-09
Nektar Therapeutics USD -34.7M 2.35M 2025-12
Neurocrine Biosciences USD 246.8M 7.4M 2026-03
Otsuka Holdings JPY 130.23B 54.96B 2026-03
Pfizer USD 5.18B 6.82B 2026-03
Regeneron Pharmaceuticals USD 1.04B 719.6M 2025-12
Vertex Pharmaceuticals USD 1.25B 78.1M 2026-03